Michael A. Olaopa, Ph.D. Email & Phone Number

Philadelphia, Pennsylvania, United States

Philadelphia, Pa, Us

Role Overview:• Portfolio and Clinical Trial Support: Provide non-clinical expertise for assets in the portfolio, focusing on Phase I/II clinical trials.• Team Leadership: Lead high-performing teams in a deadline-driven environment, ensuring achievement of critical milestones and deliverables.• External Collaboration: Engage with Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) to harness external resources and specialized knowledge.• Research and Development Guidance: Direct research and IND-enabling activities to advance candidates from pre-portfolio stages into the portfolio.Core Competencies:• Clinical Biomarker Strategy: Inform and refine clinical biomarker strategies to optimize therapeutic outcomes.• Clinical Decision-Making: Enable informed clinical decision-making processes through data-driven insights.• Regulatory Support: Facilitate regulatory submissions with comprehensive non-clinical data and documentation.• Next-Generation Drug Development: Drive the development of innovative therapies by reverse-translating clinical insights into actionable research.

San Diego, California, Us

Michael led engagements with external KOLs and SMEs in biotech and pharma to develop, implement, and communicate tailored high-content in vitro assays for screening small molecules, monoclonal antibodies, and test-articles. Over a 20-month period, he collaborated with stakeholders to achieve research milestones and managed key client accounts with a combined budget of $1.2M.Project Management; Client Engagement and KOL Management; Assay Design and Data Analyses; Team Building.Therapeutic Areas: Cardiovascular, Neuroscience, Liver, Oncology, Gene Therapy.

San Diego, California, Us

Leadership: KOL Engagement; Client Relationship Building; Project Management. Therapeutic Areas: Cardiovascular, Neuroscience, Liver, Oncology, Gene Therapy.Technical: In-Vitro Assay Development (iPSC / Stem Cells, Primary Cells); High Content Screening and Imaging Analyses; Spheroid and 3D Organoid Cell Modeling; Cell Painting; In Vitro Pharmacology and Compound Testing.Imaging Platforms: ThermoFisher CellInsight CX7 LZR, GE INCell 6500 HS, Yokogawa CQ1, Incucyte Live-Cell.Tools: Asana, Quartzy, Python, BioRender.

Los Angeles, Ca, Us

Michael collaborated with HCPs to build pre-clinical models of cardiovascular failure, which could quantify neurological, physiological, and functional alterations that occur in the cardiac conduction system after a myocardial infarction (heart attack).Publication:"Heterogeneous cardiac sympathetic innervation gradients promote arrhythmogenesis in murine dilated cardiomyopathy". JCI Insight, Oct 2023. doi: 10.1172/jci.insight.157956.

Portland, Oregon, Us

Michael conceptualized and led a collaborative study to assess the effects of a novel small molecule on the cardiac sodium ion channel and heart function. This small molecule is currently being developed as a therapeutic against triple-negative breast cancer by interacting with Lamin-A/C, a protein that Michael et al. had previously shown to be important in patients with cardiac conduction disease and heart failure. The results of this study demonstrated, for the first time, that region-specific post-translational modifications of Lamin-A/C has a functional impact on the heart. These findings have the potential to influence clinical development of therapeutics targeted against breast cancer and cardiac conduction disease.Publication:"Phosphorylation of Lamin A/C at serine 22 modulates Nav1.5 function". Physiological Reports, Nov 2021. doi: 10.14814/phy2.15121.

Indianapolis, Indiana, Us

Michael designed and performed functional cardiac electrophysiology studies that delineated the underlying role of novel LMNA (Lamin-A/C) and SCN5A (Nav1.5) genetic mutations in patients with cardiac arrhythmias often associated with dilated cardiomyopathy (heart failure). In 2015, Michael was invited to present the findings of his research at both the Heart Rhythm Society (Boston) and American Heart Association (Orlando) conferences. As a result of these and other studies, new protocols for early detection and diagnosis were established, which have led to improved health outcomes for these patients.Laboratory of Peng-Sheng Chen (MD, FAHA, FHRS)Publications:1. "Complex Arrhythmia Syndrome in a Knock-In Mouse Model Carrier of the N98S Calm1 Mutation". Circulation, Nov 2020. doi: 10.1161/CIRCULATIONAHA.120.046450.2. "Lamin-A/C Variants Found in Patients with Cardiac Conduction Disease Reduce Sodium Currents". Cardiogenetics, Feb 2018. doi: 10.4081/cardiogenetics.2018.7127.3. "Small conductance calcium-activated potassium current and the mechanism of atrial arrhythmia in mice with dysfunctional melanocyte-like cells". Heart Rhythm, Jul 2016. doi: 10.1016/j.hrthm.2016.03.011.4. "Genetic Variation of SCN5A in Korean Patients with Sick Sinus Syndrome". Korean Circulation Journal, Jan 2016. doi: 10.4070/kcj.2016.46.1.63.

Indianapolis, In, Us

Indianapolis, In, Us

Michael designed 3 novel pre-clinical therapeutic approaches, which targeted the beta-adrenergic and MAPK pathways, respectively, using 2 models of congenital heart disease in newborn patients. The results of this research led to an Excellence in Science Award (2010) from the American Association for the Advancement of Sciences (AAAS), including an Invited Membership (2011/12). Laboratory of Simon J. Conway (PhD, FAHA)Publications:1. "Neural Crest Stem Cells: Breakthroughs and Applications". World Scientific / Imperial College Press, Aug 2012.2. "Pax3 is essential for normal cardiac neural crest morphogenesis but is not required during migration nor outflow tract septation". Development Biology, May 2011. doi: 10.1016/j.ydbio.2011.05.583.3. "Riley Heart Center Symposium on Cardiac Development 2009: Transcriptional Unification of Heart Morphogenesis". Pediatric Cardiology, Feb 2010. doi: 10.1007/s00246-010-9640-x.4. "Cardiovascular development and the colonizing cardiac neural crest lineage". Scientific World Journal, Jul 2007. doi: 10.1100/tsw.2007.189. 5. "Identification and characterization of a novel Schwann and outflow tract endocardial cushion lineage-restricted periostin enhancer". Development Biology, May 2007. doi: 10.1016/j.ydbio.2007.04.041.

Phd, Medical And Molecular Genetics

Mba-Level Postgraduate Certificate, Business Of Life Sciences

Bs, Cells, Molecules, And Systems Biology

Ssce